Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of ME2136 plus standard antiemetic therapy for prevention of cisplatin-induced nausea and vomiting
jRCT2041240050Phase 2Recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Complete response in the delayed phase. Started Jul 2024; status: recruiting.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT2041240050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240050.